Bristol-Myers Squibb Company (BMY) 31.90 -0.09

Bristol-Myers Squibb Co.
(BMY) 31.90 -0.09

Last Trade:	31.90	Day Range:	31.65 - 31.94
Trade Time:	04:02PM	52wk Range:	24.97 - 35.42
Prev. Close:	31.99	Market Cap:	54.06B
Open:	31.75	Div Yield:	4.17
Volume:	8086838	PE:	150
EPS:	2.16

The Latest On BMY

Trovagene: Built on Experience and Ready to Move Higher 2/9/12 1:08pm

Benzinga's M&A Chatter for Wednesday February 8, 2012 2/8/12 7:59pm

From Earlier: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex 2/8/12 8:20am

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc. 2/3/12 7:30am

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex 2/3/12 7:30am

Two Biotechs That Continue to Attract Positive Attention From Investors 2/1/12 8:50am

UPDATE: Bristol-Myers Squibb Reports Rise In Q4 Earnings 1/26/12 9:05am

Earnings Scheduled For January 26 1/26/12 1:33am

BioLineRx Surges after Hep C License Agreement 1/24/12 10:23am

Earnings Expectations for the Week of January 23 1/22/12 2:13pm

Morgan Stanley Downgrades Bristol Myers-Squibb to Equal-weight 1/19/12 10:16am

Achillion's Hep C Pipeline Likely Can't Compete 1/19/12 9:03am

Trovagene: Built on Experience and Ready to Move Higher 2/9/12

Benzinga's M&A Chatter for Wednesday February 8, 2012 2/8/12

From Earlier: Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex 2/8/12

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc. 2/3/12

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex 2/3/12

Two Biotechs That Continue to Attract Positive Attention From Investors 2/1/12

UPDATE: Bristol-Myers Squibb Reports Rise In Q4 Earnings 1/26/12

Earnings Scheduled For January 26 1/26/12

BioLineRx Surges after Hep C License Agreement 1/24/12

Earnings Expectations for the Week of January 23 1/22/12

Morgan Stanley Downgrades Bristol Myers-Squibb to Equal-weight 1/19/12

Achillion's Hep C Pipeline Likely Can't Compete 1/19/12

Trovagene: Built on Experience and Ready to Move Higher 2/9/12

Benzinga's M&A Chatter for Wednesday February 8, 2012 2/8/12

Two Biotechs That Continue to Attract Positive Attention From Investors 2/1/12

Earnings Scheduled For January 26 1/26/12

Earnings Expectations for the Week of January 23 1/22/12

S&P Lukewarm On New Low Volatility ETFs 1/17/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Benzinga's M&A Chatter for Monday January 9, 2012 1/9/12

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Forget Dendreon, Inhibitex is the New Biotech Success Story 1/9/12

Financial Breakfast: Morning News Summary for January 9, 2012 1/9/12

Stocks To Watch For January 9 1/9/12

Morgan Stanley Downgrades Bristol Myers-Squibb to Equal-weight 1/19/12

S&P Lukewarm On New Low Volatility ETFs 1/17/12

UPDATE: McNicoll Lewis & Vlak Downgrades Inhibitex to Hold 1/13/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Bank of America Raises PO on Idenix Pharmaceuticals to $18 1/9/12

Financial Breakfast: Morning News Summary for January 9, 2012 1/9/12

Brean Murray Raises PT on Inhibitex to $26 1/9/12

Bank of America Merrill Lynch Provides Update on Bristol-Myers Squibb 1/4/12

Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure 12/23/11

BofA Reiterates Neutral, $34 PT On Bristol-Myers 12/8/11

Bank of America Reiterates Neutral on Bristol-Myers Squibb 11/29/11

Deutsche Bank Reiterates Buy on Bristol-Myers Squibb 11/29/11

Trade BMY
NOW!

Partner Headlines

YCHARTS DIVIDEND DAILY: Dividends Are Hot – Help For Finding Some Below – But Know the Risks, Too 2/10/12

Sanofi Beats Earnings Estimates - Analyst Blog 2/10/12

Johnson & Johnson (JNJ) - A Reliable Dividend Growth Stock 2/10/12

Healthy Health Care ETF? 2/9/12

Positive Results on Forest/Gedeon Drug - Analyst Blog 2/9/12

Bristol-Myers, SNY Win Plavix Damages - Analyst Blog 2/9/12

Ten Big Pharma Stocks' Juicy Dividend Payouts, With Cash-on-Hand as Cushion 2/8/12

Higher Bleeding Haunts Merck Candidate - Analyst Blog 2/8/12

The Stocks James Barrow Is Selling 2/8/12

Earnings Scorecard: Bristol-Myers - Analyst Blog 2/6/12

Pfizer Shrugs Off the Loss Of Lipitor (PFE, MRK, BMY, FRX, LLY) 2/6/12

Who Wants Free Money with Inhibitex? 2/3/12

Press Releases

Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference 2/8/12 Business Wire Story

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex 2/8/12 Business Wire Story

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc. 2/3/12 Business Wire Story

Bristol-Myers Squibb Delivers Solid Fourth Quarter Capping a Year Highlighted by New Product Approvals, Continued Execution of Strategic Transactions and Good Operating Performance 1/27/12 Business Wire Story

Bristol-Myers Squibb Names Gerald L. Storch to Board of Directors 1/24/12 Business Wire Story

Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin 1/19/12 Business Wire Story

First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published 1/18/12 Business Wire Story

Bristol-Myers Squibb Begins Tender Offer to Acquire Inhibitex, Inc. 1/13/12 Business Wire Story

Critical Alerts for Aflac, Bristol-Myers Squibb, Intuit, Eaton, and Perrigo Released by Seven Summits Research 1/11/12 Newswire Story

The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Inhibitex, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Co. 1/10/12 Business Wire Story

Faruqi & Faruqi, LLP Announces Investigation of Inhibitex, Inc. 1/10/12 Business Wire Story

Get the latest BMY stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Bristol-Myers Squibb Co. stock price.

Bristol-Myers Squibb Co. by YCharts